Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2014 1
2015 2
2017 1
2018 1
2019 2
2020 1
2021 1
2022 3
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean klein o profile (50 results)?
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.
Plum-Mörschel L, Klein O, Singh G, Murugesan SMN, Marwah A, Sharma N, Panda J, Loganathan S, Lakshmi GC, Athalye SN. Plum-Mörschel L, et al. Among authors: klein o. Diabetes Obes Metab. 2022 Sep;24(9):1819-1828. doi: 10.1111/dom.14768. Epub 2022 Jun 6. Diabetes Obes Metab. 2022. PMID: 35589611 Free PMC article. Clinical Trial.
Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
Leohr J, Kazda C, Liu R, Reddy S, Dellva MA, Matzopoulos M, Loh MT, Hardy T, Klein O, Kapitza C. Leohr J, et al. Among authors: klein o. Diabetes Obes Metab. 2022 Feb;24(2):187-195. doi: 10.1111/dom.14561. Epub 2021 Oct 27. Diabetes Obes Metab. 2022. PMID: 34605142 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes.
Heise T, Chien J, Beals JM, Benson C, Klein O, Moyers JS, Haupt A, Pratt EJ. Heise T, et al. Among authors: klein o. Diabetes Obes Metab. 2023 Apr;25(4):1080-1090. doi: 10.1111/dom.14956. Epub 2023 Jan 9. Diabetes Obes Metab. 2023. PMID: 36541037
BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode B. Heise T, et al. Among authors: klein o. Diabetes Obes Metab. 2019 Apr;21(4):1066-1070. doi: 10.1111/dom.13621. Epub 2019 Jan 17. Diabetes Obes Metab. 2019. PMID: 30565407 Clinical Trial.
Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes.
Meiffren G, Herbrand T, Anastassiadis E, Klein O, DeVries JH, Heise T, Alluis B, Mégret C, Gaudier M, Soula O, Plum-Mörschel L. Meiffren G, et al. Among authors: klein o. Diabetes Obes Metab. 2019 Jul;21(7):1570-1575. doi: 10.1111/dom.13685. Epub 2019 Apr 8. Diabetes Obes Metab. 2019. PMID: 30828929 Clinical Trial.
Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
Bailey TS, Pettus J, Roussel R, Schmider W, Maroccia M, Nassr N, Klein O, Bolli GB, Dahmen R. Bailey TS, et al. Among authors: klein o. Diabetes Metab. 2018 Feb;44(1):15-21. doi: 10.1016/j.diabet.2017.10.001. Epub 2017 Nov 16. Diabetes Metab. 2018. PMID: 29153485 Free article. Clinical Trial.
13 results